At a Glance
What it is: A pre-blended single vial containing four separately studied peptides: BPC-157, TB-500 (Thymosin Beta-4), GHK-Cu, and KPV.
Researchers have studied the components for: soft-tissue and tendon repair in animals (BPC-157), wound closure and new blood vessel growth (TB-500), matrix remodeling and repair signaling in skin cells (GHK-Cu), and inflammatory signaling in gut and immune cells (KPV).
Evidence level: Each compound has its own preclinical literature, mostly animal and lab-dish work, with a small amount of human data on Thymosin Beta-4. There is no controlled trial of the four compounds together.
The short version: KLOW is four peptides in one vial. Each has been studied on its own, and this page summarizes that work compound by compound. What has not been studied is the combination. No trial has tested these four together, in any species, so anything said about how they behave as a group is inference rather than evidence. That gap is stated here rather than papered over.
KLOW is a blend, not a compound. It is four separate peptides supplied pre-mixed in a single vial, and each of the four carries its own research history that has nothing to do with the other three.
That structure shapes what an honest page can say. Below is what researchers looked at for each component, in what kind of model, and what they observed. Then a section on what the combination does not have, which is the part most pages in this category skip.
What KLOW is made of
Four peptides, each with a separate literature and a separate page on this site:
- BPC-157, a synthetic fragment derived from a protein found in gastric juice, studied for soft-tissue repair. Full research summary
- TB-500, the research name used for Thymosin Beta-4, a naturally occurring peptide studied for wound closure. Full research summary
- GHK-Cu, a copper-binding tripeptide studied for matrix remodeling in skin. Full research summary
- KPV, the three-amino-acid tail of the hormone alpha-MSH, studied for anti-inflammatory activity. Full research summary
This page does not restate the amount of each. What follows is the research on each compound as a compound.
What researchers have studied
BPC-157
Ligament healing in rats (Journal of Orthopaedic Research, 2010). Researchers cut the knee ligament in rats and gave BPC-157 by several routes over 90 days. They observed better functional recovery and better structural healing in the treated animals. Live animal model, not people. PMID 20225319. https://pubmed.ncbi.nlm.nih.gov/20225319/
Achilles tendon-to-bone healing in rats (Journal of Orthopaedic Research, 2006). This study looked at how a detached Achilles tendon reattached to bone in rats. Treated animals healed faster, and BPC-157 offset some of the harm corticosteroids caused in that model. PMID 16583442. https://pubmed.ncbi.nlm.nih.gov/16583442/
Review of the soft-tissue research (Cell and Tissue Research, 2019). A review pulled together the musculoskeletal studies and reported consistent healing effects across the animal work. The authors were clear that the evidence is preclinical and that human efficacy is not confirmed. PMID 30915550. https://pubmed.ncbi.nlm.nih.gov/30915550/
TB-500 (Thymosin Beta-4)
Wound healing in rats (Journal of Investigative Dermatology, 1999). Researchers applied Thymosin Beta-4 to skin wounds in rats, on the surface and by injection. They observed new skin cover over the wound rise by 42 to 61 percent, with faster skin-cell migration. PMID 10469335. https://pubmed.ncbi.nlm.nih.gov/10469335/
Human venous ulcer trial (Annals of the New York Academy of Sciences, 2007). A European randomized study put topical Thymosin Beta-4 on venous leg ulcers in 72 patients over 84 days. It was mainly a safety and tolerability study, and researchers reported a signal toward faster healing at certain doses. This is one of the few human data points anywhere in this blend. PMID 17495250. https://pubmed.ncbi.nlm.nih.gov/17495250/
Skin-healing review (Vitamins and Hormones, 2016). A review summarizing the dermal research, including Phase 2 results in patients with pressure ulcers, stasis ulcers, and a blistering skin condition, alongside animal work. PMID 27450738. https://pubmed.ncbi.nlm.nih.gov/27450738/
GHK-Cu
Copper and matrix remodeling in fibroblasts (Siméon, Life Sciences, 2000). An in vitro study using cultured rat dermal fibroblasts, meaning isolated cells in a lab dish. Researchers observed that GHK-Cu raised levels of MMP-2, an enzyme that reshapes the extracellular matrix, along with two matrix inhibitors. The copper ion drove the effect, not the peptide alone. PMID 11045606. https://pubmed.ncbi.nlm.nih.gov/11045606/
Growth-factor expression in stressed fibroblasts (Pollard, Archives of Facial Plastic Surgery, 2005). An in vitro study of human fibroblasts, some of them irradiated to model tissue injury. Researchers recorded faster cell doubling and higher output of two repair signals, bFGF and VEGF, in the treated cells. PMID 15655171. https://pubmed.ncbi.nlm.nih.gov/15655171/
Gene-expression review (Pickart and Margolina, International Journal of Molecular Sciences, 2018). A review built on gene-profiling data, mapping the pathways GHK appears to touch. This is an interpretation of prior data, not an experiment. PMID 29986520. https://pubmed.ncbi.nlm.nih.gov/29986520/
KPV
KPV uptake and gut inflammation (Gastroenterology, 2008). Researchers tested KPV in intestinal and immune cells and in two mouse colitis models. They reported that a transporter called PepT1 carried KPV into cells, where it lowered inflammatory signaling and cut pro-inflammatory cytokines. This mixes lab-dish cells and live animals, not people. PMID 18061177. https://pubmed.ncbi.nlm.nih.gov/18061177/
KPV in two colitis models (Inflammatory Bowel Diseases, 2008). A mouse study using DSS-induced colitis and a transfer colitis model. Treated mice recovered sooner and showed less inflammation in gut tissue. Live animal model. PMID 18092346. https://pubmed.ncbi.nlm.nih.gov/18092346/
Review of alpha-MSH and its tripeptides (Endocrine Reviews, 2008). A review, not a new experiment. The authors described consistent anti-inflammatory effects across models, without the pigment effects of the full hormone, and framed it as early-stage potential rather than settled human use. PMID 18612139. https://pubmed.ncbi.nlm.nih.gov/18612139/
How it works
There is no single mechanism for KLOW, because KLOW is not a single compound. There are four mechanisms, each proposed for a different peptide, and each still being mapped.
BPC-157 has been linked in animal work to new blood vessel formation, with researchers reporting raised VEGF during muscle and tendon repair. Thymosin Beta-4 binds actin, a structural protein inside cells, and the research ties that to cell migration and to new vessel growth at a wound edge. GHK-Cu carries a copper ion, and the copper appears to be doing much of the work, shifting the enzymes that build and reshape the extracellular matrix. KPV appears to quiet two inflammation switches called NF-kB and MAPK, which lowers the output of inflammatory messengers.
Read those four together and a reader will notice they touch related territory. Repair signaling, vessel growth, matrix building, inflammatory tone. That observation is not a finding. Nobody has run the experiment that would turn it into one, and the honest position is that four mechanisms described separately in separate models remain four separate mechanisms until something tests them as a group.
What the research does not establish
The honest limits are the whole point here, and for a blend they are larger than for a single compound.
- No study has tested these four compounds together. Not in people, not in animals, not in cells. Every citation above concerns one compound on its own. Any account of how the four behave as a group is inference.
- A combination is not the sum of its parts. Compounds can interfere with each other, compete for the same transport, or change each other’s stability in solution. None of that has been characterized for this blend.
- Most of the underlying work is preclinical. BPC-157, GHK-Cu, and KPV rest almost entirely on animal and lab-dish models. Thymosin Beta-4 has the most human data, and even that is early trial work on wounds and eye surfaces rather than on anything else.
- None of the four is an FDA-approved drug. No approved human use exists for any component of this blend.
- Animal and cell results do not transfer. What happened in a mouse colitis model or a dish of irradiated fibroblasts does not tell you what would happen in a person.
- Nothing here is a safety conclusion. This is a research summary, not evidence that any of it is safe to use, alone or combined.
Anyone telling you the combination is proven is ahead of the research, and quite a long way ahead of it.
For Research Use Only. Not for human consumption. Etched Research supplies compounds for laboratory and research use only. Nothing on this page is medical advice, a health claim, or a recommendation to use.
Available at Etched Research. Research-grade material, supplied as a pre-blended single vial. For research use only. View product →